Onkologie. 2024:18(1):22-24 | DOI: 10.36290/xon.2024.005

Treatment of metastatic endometrial carcinoma

Veronika Novotná, Denisa Pohanková
Klinika onkologie a radioterapie, FN Hradec Králové

Malignant tumors of the uterine body are the most common gynecological malignancy in developed countries. In advanced stages, approximately 10-15 % of patients are dia­gnosed. The treatment of metastatic endometrial carcinoma has advanced in recent years, thanks in part to the diverse molecular profile of the disease. In addition to surgical and radiotherapeutic approaches, not only cytotoxic chemotherapy but also immunotherapy, hormonal therapy, and targeted treatment are available. This article provides an overview of the currently used treatments for this condition in the Czech Republic.

Keywords: metastatic endometrial carcinoma, hormonal therapy, immunotherapy, targeted treatment in metastatic endometrial carcinoma.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotná V, Pohanková D. Treatment of metastatic endometrial carcinoma. Onkologie. 2024;18(1):22-24. doi: 10.36290/xon.2024.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zhang M, Li R, Zhang S, et al. Analysis of prognostic factors of metastatic endometrial cancer based on surveillance, epidemiology, and end results database. Frontiers in Surgery. 2023;9:1001791. Go to original source... Go to PubMed...
    2. Available from: www.svod.cz.
    3. Tinker AV, Dhani NC, Ghatage P, et al. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer. Therapeutic Advances in Medical Oncology. 2023;15:17588359231157633.Další literatura u autorky a na www.onkologiecs.cz Go to original source... Go to PubMed...
    4. Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA: a cancer journal for clinicians. 2019;69(4):258-279. Go to original source... Go to PubMed...
    5. Pignata S, Scambia G, Schettino C, et al. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 2023;24(3):286-296. Go to original source... Go to PubMed...
    6. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecologic Cancer. 2021;31:1. Go to original source... Go to PubMed...
    7. Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). Journal of Clinical Oncology. 2020;38(33):3841. Go to original source... Go to PubMed...
    8. Fleming Gini F. Second-line therapy for endometrial cancer: the need for better options. Obstetrical & Gynecological Survey. 2016;71(7):406-408. Go to original source...
    9. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecologic onkology. 2007;106(2):325-333. Go to original source... Go to PubMed...
    10. Mileshkin L, Edmondson R, O'Connell RL, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial-ANZGOG 0903. Gynecologic Oncology. 2019;154(1):29-37. Go to original source... Go to PubMed...
    11. Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. Journal of Clinical Oncology. 2015;33(8):930. Go to original source... Go to PubMed...
    12. Petrelli F, Ghidini M, Ghidini A, et al. Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA onkology. 2020;6(7):1068-1071. Go to original source... Go to PubMed...
    13. Park JY, Lee JY, Lee YY, et al. Major clinical research advances in gynecologic cancer in 2021. Journal of Gynecologic Oncology. 2022;33:2. Go to original source... Go to PubMed...
    14. Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study. Journal for immunotherapy of cancer. 2022;10:1. Go to original source... Go to PubMed...
    15. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. New England Journal of Medicine. 2023;388:2145-2158. Go to original source... Go to PubMed...
    16. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet Oncology. 2020;21(10):1353-1365. Go to original source... Go to PubMed...
    17. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. New England Journal of Medicine. 2023;388:2159-2170. Go to original source... Go to PubMed...
    18. Vermij L, Horeweg N, Leon-Castillo A, et al. HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes. Cancers. 2020;13(1):44. Go to original source... Go to PubMed...
    19. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. PMID: 29584549. Go to original source... Go to PubMed...
    20. Makker V, Colombo N, Herráez AC, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. New England Journal of Medicine 2022;386(5):437-448. Go to original source... Go to PubMed...
    21. Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast cancer research and treatment. 2020;183:419-428. Go to original source... Go to PubMed...
    22. Mirza MR, Bjørge L, Marmé F, et al. LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO/ENGOT-EN3 trial. Annals of Oncology. 2020,31:S1160. Go to original source...
    23. Miyasaka A, Oda K, Ikeda Y, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC cancer. 2014;14:1-10. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.